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DOI 10.1186/s12962-014-0027-3RESEARCH Open AccessAn approach to prioritization of medical devices
in low-income countries: an example based on
the Republic of South Sudan
Richard J Lilford1,2*, Samantha L Burn1, Karin D Diaconu1, Peter Lilford3, Peter J Chilton1, Victoria Bion4,
Carole Cummins1 and Semira Manaseki-Holland1Abstract
Background: Efficient and evidence-based medical device and equipment prioritization is of particular importance in
low-income countries due to constraints in financing capacity, physical infrastructure and human resource capabilities.
Methods: This paper outlines a medical device prioritization method developed in first instance for the Republic of
South Sudan. The simple algorithm offered here is a starting point for procurement and selection of medical devices
and can be regarded as a screening test for those that require more labour intensive health economic modelling.
Conclusions: A heuristic method, such as the one presented here, is appropriate for reaching many medical device
prioritization decisions in low-income settings. Further investment and purchasing decisions that cannot be reached so
simply require more complex health economic modelling approaches.
Keywords: Medical devices, Equipment, Prioritization, Purchasing, Selection, Low-income countryBackground
This paper originated in a prioritization task assigned to
Richard Lilford (RJL) by the Procurement Agent (Frannan
International) for the pre-independence government of
South Sudan in 2010. At that time South Sudan had re-
cently emerged from Africa’s longest civil war. It was mov-
ing towards independence (which it achieved in 2011) and
an interim government was in place. The country had
some of the worst health indicators in the world with high
infant and maternal mortality rates [1], endemic malaria,
and a high prevalence of tuberculosis [2]. Health spending
was low, amounting to US$23 per capita (combining gov-
ernment and aid contributions) [3]. The interim govern-
ment wished to replenish the depleted inventory of capital
stock in the three major hospitals that fell under its direct
control (Juba, Wau and Malakal). Each of these hospitals
was connected to mains electricity supply, but this was* Correspondence: r.j.lilford@bham.ac.uk
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unless otherwise stated.frequently interrupted, and while the hospitals had two
generators, fuel supply and maintenance was intermittent.
Supply chains for devices were unreliable and there was
no capacity for on-site repairs. There was also a limited
supply of skilled doctors with only 34 specialists [4] to
serve a population of 10.9 million [5]. Against this back-
ground, the Department of Health commissioned a junior
doctor, Jordan Lawrence, to visit each hospital and draw
up a ‘long list’ of items nominated for procurement by
clinical staff. The result was an unprioritized inventory of
258 devices, ranging from a corner cabinet to a magnetic
resonance imaging (MRI) scanner (Additional file 1). This
paper describes the method we developed to tackle the
prioritization problem for devices. We developed a set of
principles and hence a simple flow chart to help the priori-
tisation task and offer it here in the hope that it may be
useful to others who have to adapt priorities for their
specific localities.Method development
It was immediately apparent that there was insufficient
time and resource to carry out a cost-effectiveness analysis
on all 258 of the requested items. In addition, it would beThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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needles on the basis of a formal economic model, such as
those designed to estimate Disability Adjusted Life Years
(DALYs) or Quality Adjusted Life Years (QALYs). A
method was needed that could identify items for procure-
ment based on informal judgment without the need to
carry out a formal and time-consuming health economic
evaluation. RJL developed a first draft of the method
during his six-day sojourn in Juba in 2010 in response to
the problem presented to him. He and his co-authors then
developed the method further as follows.
A systematic review was conducted of the literature on
device prioritization. [Work in progress: Diaconu K, Burn
S, Chen Y-F, Manaseki-Holland S, Cummins C, Lilford R:
“Methods for medical device and equipment procurement
within low- and middle-income countries: Findings of a
systematic literature review”]. We found many lists of
devices considered essential for health facilities [6,7] or for
packages of services, for example those covering maternal
health and diagnosis of tuberculosis [8,9]. With a few ex-
ceptions (discussed below) these have been developed by
professional consensus rather than an explicit health eco-
nomic model. We also found decision frameworks, some
incorporating health economic routines, for the develop-
ment of composite services [10-12]. However, we did not
find a simple framework or checklist that could have been
deployed in the context of the assigned prioritization task.
The method was further refined iteratively on the basis
of feedback following a presentation at an expert
research workshop "Methods of Health Technology
Assessment and Priority Medical Devices for low- and
middle-income countries" (Hilton Metropole Hotel,
Birmingham, UK, October 2013) and the World Health
Organization (WHO) Second Global Forum on Medical
Devices (Geneva, Switzerland, November 2013).
A framework for medical device prioritization in
low-income settings
A number of principles could be derived on the basis of
the literature review and the expert group described
above. These principles are enshrined in the steps within
the framework.
The screening algorithm is comprised of five decision-
gates, each based on a defendable principle. The frame-
work is represented in Figure 1, where we give examples
of devices excluded or included at different decision-
gates. We illustrate our approach with respect to thir-
teen devices from the long list – Table 1.
First decision-gate: is the device a “bare essential”?
Some items can be included on the grounds that they are
bare essentials. More formally, items in this category share
three features. First, they are simple devices that do not
require special skills and do not rely on a continuousexternal power supply (factors considered in more detail
with respect to the following decision-gate). Second, their
cost is low relative even to other things that are purchased
in the country concerned; more formally they are judged
to fall under the cost-effectiveness threshold for the coun-
try concerned – a point to which we return. Third, their
benefits are spread across many situations, disease classes
and patient types, as in the case of surgical gloves, needles
and syringes. The cost of calibrating, valuing and model-
ling such an array of technology applications is judged to
be incommensurate with the cost of doing so; nobody uses
health economic models to prioritise this type of device.
The weighing machine, corner cabinet, blood pressure
machine and oxygen regulator were selected on these
grounds. Many items in this category are included in the
WHO Core Medical Equipment list, but it is always im-
portant to customise selection for local contexts; as stated
in the document “It is […] impossible to make a list of
core medical equipment which would be exhaustive and/
or universally applicable” [13].
Second decision-gate: is the device usable?
Items that are not prioritised at the first decision-gate
are analysed as to how they are likely to fare in the pro-
posed environment. That is to say, based on local know-
ledge, can the proposed device be supported by the
following:
1. The physical infrastructure currently available, or
credibly attainable, by the time the technology is
deployed. Such infrastructure includes electricity
supply, running water, temperature control, storage
space, safety factors (especially for radiology
equipment) and sterilisation.
2. The human resources that are, or realistically could be,
in place by the time the technology is deployed [14,15].
Staff in low-income countries may not have had an
opportunity to acquire skills to use the requested
equipment safely. The salient question under these
circumstances is whether the expertise could be
acquired within the implementation time frame. If this
is unlikely or implausible, then the decision should be
deferred for a future funding round, typically a year
later. Use of some equipment items may involve
relatively minor augmentation of existing skill-sets and
hence may be rapidly acquired. In such cases the
technology would not be screened out at this stage, but
the cost of training – including the opportunity cost of
any absence from work – should be included in the
value for money consideration of the type described in
a later section.
3. The supply chain and facilities to maintain equipment
are additionally important since much equipment in
low-income countries falls into disuse for want of the
Figure 1 Flow diagram showing decision-gates: an aide-mémoire for device prioritization.
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provide the consumables and parts needed to keep the
item in use or to maintain it in serviceable condition
[16,17]. This problem can sometimes be ameliorated by
careful specification of equipment [18]. For example, an
electrocardiogram (ECG) with a display function
remains useful even if the paper supply fails. Again, if
the problem can be overcome, then the technology
should not be screened out at this stage, but any
additional costs to circumnavigate problems in the
supply chain or send items for repair abroad must be
factored into the decision.
The requested colonoscope fell short of this set of criteria
since staff with the requisite training or experience to rap-
idly acquire the necessary skills were simply not available.Third decision-gate: is a cheaper alternative available?
In some cases it may be possible to identify an alterna-
tive device that does the job just as well, but at less cost
than the device requested. One of the devices that found
its way onto the list in South Sudan was a hysteroscope,
with exclusion of endometrial cancer as its rationale. Ex-
aminations of existing literature reviews, [19-22] backed
up by consultation with a local expert, showed that it is
“dominated” by an alternative device, the Pipelle biopsy,
which is equally effective (sensitive and specific) at a
fraction of the cost. Not only is the Pipelle biopsy inex-
pensive (US$9.35 per procedure) [23], but gynaecological
and pathological expertise was available in South Sudan
to both obtain and analyse samples. Since it saves on the
cost of the existing method (dilation and curettage under
general anaesthetic) this device is not just cost-effective,
Table 1 Approximate prices (US$) for thirteen selected medical devices
Device Example Reported
price
Approx. price
(US$)
Source
MRI Scanner GBP 895,000 1,460,000 National Audit Office. Managing High Value Capital
Equipment in the NHS in England. HC 822 Session
2010–2011. London: The Stationery Office. 2011*
Regulators for Oxygen
Cylinders
KES 18,000 200 WHO Medical Equipment List for Typical District
Hospital, Kenya, 2010**
Colonoscope 25,000 WHO Core Medical Equipment, 2011†
Hysteroscope 4 mm rigid hysteroscope
Olympus Key Med
GBP 2,460 4,020 Marsh F, Kremer C, Duffy S. BJOG. 2004; 111: 243–8.
Fetal Cardiotocograph EUR 14,900 19,120 Heintz E, Brodtkorb T, Nelson N, Levin L. BJOG.
2008;115:1676–87.
Bronchoscope 3,560 WHO Core Medical Equipment, 2011†
Pulse Oximeter for Operating
Theatres
Lifebox 250 Lifebox‡
Weighing Machine (adult) KES 9,800 110 WHO Medical Equipment List for Typical District
Hospital, Kenya, 2010**
Corner Cabinet Instrument cabinet KES 50,000 560 WHO Medical Equipment List for Typical District
Hospital, Kenya, 2010**
Ultrasound Machine 25,000 WHO Core Medical Equipment, 2011†
Blood Pressure Machine Sphygmomanometer including
cuff
EU 12.40 16 Action Medeor Price List 2014§
Microscope ZEISS binocular with 4 objectives,
220 V
EUR 1338.6 1,720 Action Medeor Price List 2014§
Gynecological Examination
Table
KES 70,000 780 WHO Medical Equipment List for Typical District
Hospital, Kenya, 2010**
All non-USD prices converted using xe.com.
*http://www.nao.org.uk/wp-content/uploads/2011/03/1011822.pdf.
**http://www.who.int/medical_devices/survey_resources/medical_devices_by_facility_provincial_hospitals_kenya.pdf.
†http://whqlibdoc.who.int/hq/2011/WHO_HSS_EHT_DIM_11.03_eng.pdf.
‡http://www.lifebox.org/
§http://en.medeor.de/images/medeor-market/price-indicator/2014/09/Equipment_EN_05-09-2014.xls.
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innovation, such as use of mosquito net mesh for hernia
repair [24]. Once a ‘dominant’ device has been identified,
it should supplant the original item in the decision-making
framework.
A device also minimises costs when it will result in net
cost reductions as a result of savings downstream. A bron-
choscope was requested in South Sudan for removal of
foreign bodies in children. Since it is very difficult to leave
such a foreign body in situ in the near certain knowledge
that the affected child would become very ill and die, such
patients are sent to Kampala for treatment. Given the
documented frequency with which this occurred, it could
be shown that the procurement of an in-expensive (rigid)
bronchoscope was a cost-minimising solution, at least if
parents’ out of pocket expenses are considered.
Fourth decision-gate: is the device a component of a
multi-component service that has itself been shown to be
cost-effective in low-income settings?
Devices are included if they are a necessary (and typically
small) component of a broader service tackling a problemsuch as tuberculosis or HIV, where the service, as a whole,
has been shown to be is cost-effective. It makes no sense to
exclude an essential device where the other service compo-
nents are, or shortly will be, in place. For example, the re-
quested microscope is an essential component of strategies
for tuberculosis control deemed cost-effective by WHO-
CHOICE standards, [25] while a gynecological examin-
ation table is an essential component of cervical cancer
screening programs that have also been shown to be
cost-effective in low-income countries [26].
Fifth decision-gate: is the device cost-effective?
Devices that have not been selected or excluded at a
previous decision-gate must now be selected or ex-
cluded on the basis of costs relative to benefits. If time
and resources to construct a health economic model
are not available, then an intuitive decision must be
made. Either way, the decision is underpinned by the
theory that a device is not cost-effective if it displaces a
service that offers more value per unit of currency. This
threshold is usually based on an external reference
standard and WHO deems a ratio of 1 × GDP/capita
Lilford et al. Cost Effectiveness and Resource Allocation  (2015) 13:2 Page 5 of 7per DALY averted as “highly cost-effective”, while 3 ×
GDP/capita is regarded as “cost-effective” [25].
If resources are available, then a formal cost-effectiveness
analysis should be considered. The methodology for such
an analysis has been explicated for high-income countries
by organisations such as the National Institute for Health
and Care Excellence (NICE) in England and the Canadian
Agency for Drugs and Technologies in Health (CADTH)
[27,28]. In addition, the WHO has produced a detailed and
intellectually rigorous tool-kit for low-income settings
[25,29]. Models need to be populated with data and good
evidence may be hard to find in a low-income context with
the result that cost-effectiveness calculations have wide
margins of error. The WHO guideline recommends assum-
ing technology is to be deployed at 80% of its capacity, but
devices are often rendered unserviceable in their expected
lifetimes due to a lack of maintenance services. It may
therefore be appropriate to make a larger adjustment to
allow for maintenance, repairs and downtime for many
devices. Cost-effectiveness models can be assigned to one
of two broad classes. The first class is a ‘sectoral’ analysis,
whereby many interventions are compared in order to
select a mix that maximises health benefit. One advantage
of this approach is that it does not assume that current
practice is itself cost-effective, and it is the method pre-
ferred by the WHO guide [25]. The alternative method
is based on a calculation of the incremental cost-
effectiveness of a particular intervention given existing
practice. The result is compared with an external refer-
ence standard, as discussed above.
We used the latter method to evaluate the pulse oxim-
eter for operating theatre use, showing that it is cost-
effective under a very wide range of plausible assump-
tions [30]. The other devices that reached this point have
not been explicitly examined; we are in the process of
constructing a model for the fetal cardiotocograph, while
the hospital has acquired an ultrasound machine on the
basis of an implicit judgment that it was cost-effective,
and the MRI machine was judged cost-ineffective on the
basis that it could not clear the cost per DALY men-
tioned above (and the practical point that it would
consume all of the available budget in a hospital where
total national health expenditure was less than US$30
per capita per year).
Discussion
The method we invoke here is based on two simple
ideas, the first that applies to all treatments, and the
second that is more specific to devices:
1. It is not cost-effective to do a cost-effectiveness analysis
in all cases – some items, whether medicinal products
or devices, can be ruled in or out on simple criteria at
decision-gate one.2. Devices are fraught with ‘usability’ problems relating to
skill in use and maintenance, and decision-gate two is
designed to weed out such devices. Even if the
device is not actually eliminated on the basis of
usability issues, ‘downtime’ should be allowed for in any
model. This is recognised by the WHO who
recommend that technology is assumed to operate at
80% capacity, but we argued above that this rule of
thumb may be conservative, since 40% of devices in
resource-poor settings fall into disuse [16]. Moreover,
explicit consideration of this problem could provide a
fine-tuned assessment of the proportion of time that a
device may be out of commission in a local context,
and this might be preferable to a ‘one size fits all’
estimate.
A third idea that may be relevant relates to the notion
of ‘pro-technology bias’, where medical staff may request
devices because they provide interest (humans are by
nature ‘tool makers’) and confer status [31,32].
The decisions at gates one to four are not based on
creating and populating models – they do not follow the
step-wise process required for the calculation of ex-
pected utility. In an ideal world, all but the most uncon-
tentious decisions could be subject to such an analysis.
In the real world, most decisions are a matter of judg-
ment informed by such evidence as the decision-maker
may have gleaned. In such a world, resources for full
economic models are sparse if they exist at all. Such
resources need to be targeted where they will do most
good – in this case where there is most doubt. The
algorithm we offer is an aid to intuitive decision-making,
not a defence of it.
There are a number of WHO resources that decision-
makers can turn to, to aid decisions at the respective
decision-gates.
1. The WHO compendium of Core Medical
Equipment [13] and the WHO medical device lists
by facility/clinical area [6,8] will help in selection of
‘bare essentials’ at decision-gate one. However, the
WHO Core Medical Equipment document disclaims
that it “has not reviewed the […] cost-acceptability
of any of the technologies referred to hereafter.”
2. The WHO Core Medical Equipment document
provides an indication of physical infrastructure and
human resource requirements for various classes of
device [13] and can thus assist decision-makers at
decision-gate two. Consideration of maintenance
and spare parts may not exclude a device at
decision-gate two, but may encourage purchasers to
think carefully about the type of contract that will
maximise the sellers’ incentive to maintain the
device in use.
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cost-effectiveness of composite services, such as
tuberculosis, vaccination and HIV services, and
specify devices that are necessary, thereby assisting
analysis at decision-gate 3.
4. As mentioned earlier, the WHO has produced
excellent documents on methods for formal
cost-utility analysis applicable at decision-gate 5.
Despite the advice given on methods for cost-
effectiveness analysis, very few examples of models for
specific device evaluations can be found in the published
literature. Laparoscopic surgery [33] and implantable defi-
brillators [34] have been evaluated in middle-income
countries (Thailand and Brazil respectively), while injec-
tion devices [35] and pulse oximeters for operating theatre
use are the only examples specifically targeted at low-
income countries of which we are aware. We should men-
tion that methods other than cost-benefit or cost-utility
analysis have been proposed for choosing between alterna-
tives – for example, by aggregating mean preferences
across different attributes (outcomes) of the decision – so
called multi-criteria decision-making [36,37]. This is not
the place for a critique of this method, save to say that it is
also a relatively time intensive process and cannot be used
to bypass the need for an intuitive screening method such
as that proposed here.
In some cases, simple (“back of the envelope”) models
may suffice – for example, where a device reduces
mortality, it may prove very good value for money even
if only lives saved are taken into account and potential
quality of life improvements ignored. Such an approach
may be regarded as a compromise between a purely
intuitive decision on the one hand, and a fully specified
health economic model on the other [38].
The current paper presents a simple flow diagram (se-
quential check-list) to assist medical device prioritization
in a low-income country. The framework for prioritization
can be easily implemented at institutional or facility level
and we offer it in the expectation that the model will help
mitigate pro-technology bias and reduce waste from pur-
chase of more expensive alternatives and devices, which
fall into disuse because they cannot be supported in a local
environment.Additional file
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South Sudan hospitals.Abbreviations
CADTH: Canadian Agency for Drugs and Technologies in Health;
DALY: Disability Adjusted Life Year; MRI: Magnetic Resonance Imaging;
NICE: National Institute for Health and Care Excellence; QALY: QualityAdjusted Life Year; WHO: World Health Organization; WHO-CHOICE: World
Health Organization: CHOosing Interventions that are Cost-Effective.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RJL developed the prioritization framework, conceived and participated in
critical drafting of the manuscript; KD, SLB, SMH, CC, PL and VB participated
in the critical drafting of the manuscript; PJC conducted background
research on South Sudan and participated in the drafting of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This study was supported primarily by the EPSRC Multidisciplinary
Assessment of Technology Centre for Healthcare (MATCH) programme
(EPSRC Grant GR/S29874/01). The National Institute for Health Research
(NIHR) Collaborations for Leadership in Applied Health Research and Care
(CLAHRC) for the West Midlands, and the NIHR Senior Investigator Award
granted to RJL also contributed resources. The views expressed in this work
do not necessarily reflect those of the funders.
We thank Drs Philippa Lilford (Taunton NHS Hospital) Jonathan Pons (Good
Shepherd Hospital, Swaziland) and Derek Barrett (previously Ngwelezane
Hospital, Empangeni, Twa Zulu Natal, Swaziland) for advice about pulse
oximetry in a developing country; Drs Gladji Varghese and Joyce Mareverwa
(Good Shepherd Hospital, Swaziland) for advice on foreign bodies in the
tracheo-bronchial tree; Dr Kambale (Good Shepherd Hospital, Swaziland) for
advice on CTG monitoring; Drs Janesh Gupta and Andrew Reid (University of
Birmingham) for the advice on hysteroscopy and bronchoscopy respectively;
and Dr Jordan Lawrence for preliminary field-work and compiling the long-list
of devices requested by clinicians in South Sudan’s three main teaching
hospitals.
Author details
1Public Health, Epidemiology and Biostatistics, School of Health and
Population Sciences, College of Dental and Medical Sciences, University of
Birmingham, Edgbaston, West Midlands B15 2TT, UK. 2Warwick Centre for
Applied Health Research and Delivery, University of Warwick, Coventry CV4
7AL, UK. 3Ministry of Finance, Government of South Sudan, Juba, South
Sudan. 4School of Medicine, University of Southampton, Southampton SO17
1BJ, UK.
Received: 18 February 2014 Accepted: 15 December 2014
References
1. Ministry of Health, G. of S. S., Southern Sudan Commission for Census, S.
and E. Southern Sudan Household Health Survey. 2006;304.
2. Ministry of Health, G. of S. S. The basic package of health and nutrition
services in secondary and tertiary health care. 2006;43.
3. Ministry of Finance and Economic Planning South Sudan. Republic of South
Sudan Donor Book. 2012;152.
4. Achiek M, Lado D. Mapping the specialist medical workforce for Southern
Sudan: devising ways for capacity building. South Sudan Med J.
2010;3(2):6–9.
5. National Bureau of Statistics, S. S. South Sudan Statistical Yearbook. 2011;67.
6. World Health Organization. List of medical devices by health care facility
Health Post - Outpatient. 2010.
7. World Health Organization. List of medical devices by health care facility
Specialized Hospital - Diagnostic. 2010.
8. World Health Organization, John Snow Inc., World Bank, PATH, United
Nations Population Fund, Population Action International. Interagency List
of Essential Medical Devices for Reproductive Health. 2008.
9. World Health Organization. Guidance for countries on the specifications for
managing TB laboratory equipments and supplies. 2011.
10. Musgrove P, Fox-Rushby J. Disease Control Priorities: Chapter 15
Cost-Effectiveness Analysis for Priority Setting. In Disease Control Priorities in
Developing Countries (2nd Edition). 2006;p. 271–286.
11. Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for
tuberculosis control in developing countries. BMJ (Clin Res Ed). 2005;331
(7529):1364. doi:10.1136/bmj.38645.660093.68.
Lilford et al. Cost Effectiveness and Resource Allocation  (2015) 13:2 Page 7 of 712. Borras C, PAHO, WHO. Organization, Development, Quality Assurance and
Radiation Protection in Radiology Services: Imaging and Radiation Therapy.
1997.
13. World Health Organization. Core Medical Equipment. 2011.
14. World Health Organization. Medical devices: Managing the Mismatch
(An outcome of the Priority Medical Devices project). 2010.
15. Keller JP, ECRI. Instructions included? Materials management in Health Care.
2010;26–9.
16. Perry L, Malkin R. Effectiveness of medical equipment donations to improve
health systems: how much medical equipment is broken in the developing
world? Med Biol Eng Comput. 2011;49(7):719–22. doi:10.1007/s11517-011-0786-3.
17. World Health Organization. (n.d.). Procurement process resource guide WHO
Medical device technical series. 2011.
18. Temple-Bird C, Kaur M, Lenel A, Kawohl W. How to manage series for
healthcare technology: Guide 5 How to Organize the Maintenance of Your
Healthcare Technology. TALC. 2005.
19. Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of
endometrial sampling in the diagnosis of patients with endometrial
carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89(8):1765–72.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11042572.
20. van Dongen H, de Kroon CD, Jacobi CE, Trimbos JB, Jansen FW. Diagnostic
hysteroscopy in abnormal uterine bleeding: a systematic review and
meta-analysis. Int J Obstet Gynaecol. 2007;114(6):664–75.
doi:10.1111/j.1471-0528.2007.01326.x.
21. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of
hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a
systematic quantitative review. JAMA. 2002;288(13):1610–21. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/12350192.
22. Yasmin F, Farrukh R, Kamal F. Efficacy of pipelle as a tool for endometrial
biopsy. 2007;23,12–5.
23. Fakhar S, Saeed G, Khan A, Alam A. Validity of pipelle endometrial sampling
in patients with abnormal uterine bleeding. Ann Saudi Med.
2008;28(3):188–91.
24. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in
low- and middle-income countries: a review of the debates surrounding
decision rules. PharmacoEconomics. 2009;27(11):903–17.
doi:10.2165/10899580-000000000-00000.
25. WHO CHOICE Collaboration. WHO Guide to Cost-Effectiveness Analysis:
Making Choices in Health. (T. Tan-Torres, R. Baltussen, T. Adam, R.
Hutubessy, A. Acharya, D. B. Evans, & C. J. L. Murray, Eds.). World Health
Organization. 2003;329
26. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C,
et al. Cost-effectiveness of cervical-cancer screening in five developing
countries. N Engl J Med. 2005;353(20):2158–68. doi:10.1056/NEJMsa044278.
27. National Institute for Health and Care Excellence. NICE “What We Do.”
Retrieved August 06, 2014, from https://www.nice.org.uk/about/what-we-do.
28. Canadian Agency for Drugs and Technologies in Health. CADTH “About
CADTH.” Retrieved August 06, 2014, from http://www.cadth.ca/en/cadth
29. Laxminarayan R, Chow J, Shahid-salles SA. Chapter 2 Intervention
Cost-Effectiveness: Overview of Main Messages. In Disease Control
Priorities in Developing Countries (2nd Edition). 2006;35–86.
30. Burn SL, Chilton PJ, Gawande AA, Lilford RJ. Peri-operative pulse oximetry in
low-income countries: a cost – effectiveness analysis. Bull World Health
Organ. 2014; 92(12):858-67
31. Sorenson, C., Drummond, M., & Kanavos, P. Ensuring value for money: The
role of health technology assessment in the European Union. 2007;1–179.
32. World Health Organization. WHO: Medical Device Technical Series
Development of medical device policies. 2011.
33. Teerawattananon Y, Mugford M. Is it worth offering a routine laparoscopic
cholecystectomy in developing countries? A Thailand case study. Cost
Effectiveness Res Allocation: C/E. 2005;3:10. doi:10.1186/1478-7547-3-10.
34. Ribeiro RA, Stella SF, Camey SA, Zimerman LI, Pimentel M, Rohde LE, et al.
Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary
prevention analysis in the public sector. Value Health. 2010;13(2):160–8.
doi:10.1111/j.1524-4733.2009.00608.x.
35. Ekwueme DU, Weniger BG, Chen RT. Model-based estimates of risks of
disease transmission and economic costs of seven injection devices in
sub-Saharan Africa. Bull World Health Organ. 2002;80(11):859–70. Retrieved
from http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2567682&tool=pmcentrez&rendertype=abstract.36. Nobre FF, Trotta LT, Gomes LF. Multi-criteria decision making–an approach
to setting priorities in health care. Stat Med. 1999;18(23):3345–54. Retrieved
from http://www.ncbi.nlm.nih.gov/pubmed/10602156.
37. Baltussen R, Niessen L. Priority setting of health interventions: the need for
multi-criteria decision analysis. Cost Effectiveness Res Allocation. 2006;4:14.
doi:10.1186/1478-7547-4-14.
38. Cosh E, Girling A, Lilford R, McAteer H, Young T. Investing in new medical
technologies: a decision framework. J Commer Biotechnol. 2007;13(4):263–71.
doi:10.1057/palgrave.jcb.3050062.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
